thumbnail image
中文
HomeAbout UsDeal TeamPortfolioNewsContact Us
中文
  • Home
  • About Us
  • Deal Team
  • Portfolio
  • News
  • Contact Us
    • POWER THE COURSE OF FIGHTING DISEASES AND SAVING LIVES

      Domain expertise, global resource, long-term capital

    • PORTFOLIO NEWS

      EdiGene Announces Approval of its IND Application for its CRISPR/Cas 9 Gene-editing Hematopoietic Stem Cell Therapy ET-01 in β-thalassemia by China National Medical Products Administration
      2021年1月18日
      BEIJING, CHINA and CAMBRIDGE, MASSACHUSETTS, US – (January 18, 2021) – EdiGene, Inc. ( “Company”,...
      Gracell Biotechnologies Announces Pricing of Initial Public Offering
      2021年1月8日
      SUZHOU and SHANGHAI, China, Jan. 8, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ...
      Abbisko Therapeutics Announces the Completion of $123 Million Series D Financing Led by The Carlyle Group
      2021年1月8日
      January 8th,2021, Shanghai—Abbisko Therapeutics Co., Ltd. announced the recent completion of its...
      Transcenta Closes $105 Million in Crossover Financing  
      2020年12月23日
      HONG KONG and SUZHOU, China, and HANGZHOU, China, Dec. 23, 2020 /PRNewswire/ -- Transcenta...
      Jacobio Debuts on Hong Kong Stock Exchange
      2020年12月21日
      December 21, 2020 – Jacobio Pharmaceuticals, a clinical-stage biotech company focusing on the in...
      SciNeuro Pharmaceuticals Launches to Bring Innovative Treatments for CNS Diseases
      2020年12月8日
      SHANGHAI--(BUSINESS WIRE)--SciNeuro Pharmaceuticals (www.scineuro.com), focused on developing...
      Eluminex Biosciences, an Ophthalmology-focused Biotechnology Company,Announces Closing of $50 Million Series A Financing
      2020年11月20日
      Proceeds to fund development of novel and best-in-class therapeutics for eye diseasesCharles...
      RemeGen Debuts on Hong Kong Stock Exchange
      2020年11月9日
      November 9, 2020 – RemeGen, a Yantai, Shandong-based biotech, debuted on Hong Kong Stock Exchange...
      More Posts

    Company

     

    Shanghai

    Room2909-14, 168 Hubin Road, Huangpu District, Shanghai, China.

     

     

    Hong Kong

    Unit 902-904, Two ChinaChem Central, 26 Des Voeux Road Central, Hong Kong

     

     

    US

    2730 Sand Hill Road, Suite 130, Menlo Park, CA

    copyright © 2018 Lilly Asia Ventures all rights reserved.

    沪ICP备12003647号-1

    沪公网安备 31010102005458号

      All Posts
      ×
      LillyAsiaVentures
      Lilly Asia Ventures (LAV) is a leading biomedical venture capital firm headquartered in China, with offices in Shanghai, Hong Kong, and Palo Alto.
      http://user-assets.sxlcdn.com/images/315509/FnksTvTDur7jpExbqYminmtjWgoM.png?imageMogr2/strip/auto-orient/thumbnail/1200x630>/format/png
      Cookie Use
      We use cookies to ensure a smooth browsing experience. By continuing we assume you accept the use of cookies.
      Learn More